Biogen Slashes Price of its Alzheimer’s Treatment
Biogen Inc. (Nasdaq: BIIB) announced its decision to reduce the wholesale acquisition cost of ADUHELM® on December 20th. Slashed by 50% The company had previously debuted its Alzheimer's treatment to widespread criticism for an initial cost that could reach US$56,000...